Van ECK Associates Corp Purchases 218,688 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Van ECK Associates Corp lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 3,955,449 shares of the medical equipment provider’s stock after acquiring an additional 218,688 shares during the quarter. Van ECK Associates Corp owned approximately 1.99% of Zimmer Biomet worth $417,814,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC bought a new position in Zimmer Biomet during the fourth quarter worth about $25,000. Dunhill Financial LLC lifted its stake in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 218 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in Zimmer Biomet in the 3rd quarter worth approximately $28,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet in the 3rd quarter valued at approximately $35,000. Finally, Kentucky Trust Co bought a new stake in Zimmer Biomet during the 4th quarter valued at $39,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $98.98 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 52-week low of $97.69 and a 52-week high of $133.90. The company has a fifty day moving average of $106.91 and a 200-day moving average of $107.91. The stock has a market capitalization of $19.70 billion, a price-to-earnings ratio of 22.24, a price-to-earnings-growth ratio of 1.83 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter last year, the business earned $2.20 earnings per share. Equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.25 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a $0.24 dividend. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.97%. Zimmer Biomet’s payout ratio is currently 21.57%.

Analysts Set New Price Targets

A number of research firms have recently commented on ZBH. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday. JMP Securities reissued a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. JPMorgan Chase & Co. upgraded shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $125.00 to $128.00 in a research note on Tuesday, December 17th. Wells Fargo & Company boosted their price target on shares of Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Finally, Royal Bank of Canada lowered their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.